Now showing items 1-7 of 7

    • Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. 

      Camacho, N; Van Loo, P; Edwards, S; Kay, JD; Matthews, L; Haase, K; Clark, J; Dennis, N; Thomas, S; Kremeyer, B; Zamora, J; Butler, AP; Gundem, G; Merson, S; Luxton, H; Hawkins, S; Ghori, M; Marsden, L; Lambert, A; Karaszi, K; Pelvender, G; Massie, CE; Kote-Jarai, Z; Raine, K; Jones, D; Howat, WJ; Hazell, S; Livni, N; Fisher, C; Ogden, C; Kumar, P; Thompson, A; Nicol, D; Mayer, E; Dudderidge, T; Yu, Y; Zhang, H; Shah, NC; Gnanapragasam, VJ; CRUK-ICGC Prostate Group; Isaacs, W; Visakorpi, T; Hamdy, F; Berney, D; Verrill, C; Warren, AY; Wedge, DC; Lynch, AG; Foster, CS; Lu, YJ; Bova, GS; Whitaker, HC; McDermott, U; Neal, DE; Eeles, R; Eeles, R; Cooper, CS; Brewer, DS (2017-09-25)
      A variety of models have been proposed to explain regions of recurrent somatic copy number alteration (SCNA) in human cancer. Our study employs Whole Genome DNA Sequence (WGS) data from tumor samples (n = 103) to comprehensively ...
    • Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital. 

      Bianchini, D; Lorente, D; Rescigno, P; Zafeiriou, Z; Psychopaida, E; O'Sullivan, H; Alaras, M; Kolinsky, M; Sumanasuriya, S; Sousa Fontes, M; Mateo, J; Perez Lopez, R; Tunariu, N; Fotiadis, N; Kumar, P; Tree, A; Van As, N; Khoo, V; Parker, C; Eeles, R; Thompson, A; Dearnaley, D; de Bono, JS (2017-10)
      The optimal management of the primary tumor in metastatic at diagnosis (M1) prostate cancer (PCa) patients is not yet established. We retrospectively evaluated the effect of locoregional treatment (LRT) on overall survival ...
    • Mutational signatures of ionizing radiation in second malignancies. 

      Behjati, S; Gundem, G; Wedge, DC; Roberts, ND; Tarpey, PS; Cooke, SL; Van Loo, P; Alexandrov, LB; Ramakrishna, M; Davies, H; Nik-Zainal, S; Hardy, C; Latimer, C; Raine, KM; Stebbings, L; Menzies, A; Jones, D; Shepherd, R; Butler, AP; Teague, JW; Jorgensen, M; Khatri, B; Pillay, N; Shlien, A; Futreal, PA; Badie, C; ICGC Prostate Group; McDermott, U; Bova, GS; Richardson, AL; Flanagan, AM; Stratton, MR; Campbell, PJ (2016-09-12)
      Ionizing radiation is a potent carcinogen, inducing cancer through DNA damage. The signatures of mutations arising in human tissues following in vivo exposure to ionizing radiation have not been documented. Here, we searched ...
    • The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. 

      Castro, E; Mikropoulos, C; Bancroft, EK; Dadaev, T; Goh, C; Taylor, N; Saunders, E; Borley, N; Keating, D; Page, EC; Saya, S; Hazell, S; Livni, N; deSouza, N; Neal, D; Hamdy, FC; Kumar, P; Antoniou, AC; Kote-Jarai, Z; PROFILE Study Steering Committee; Eeles, RA (2016-06)
      A better assessment of individualized prostate cancer (PrCa) risk is needed to improve screening. The use of the prostate-specific antigen (PSA) level for screening in the general population has limitations and is not ...
    • Prospective Study Delivering Simultaneous Integrated High-dose Tumor Boost (≤70 Gy) With Image Guided Adaptive Radiation Therapy for Radical Treatment of Localized Muscle-Invasive Bladder Cancer. 

      Hafeez, S; Warren-Oseni, K; McNair, HA; Hansen, VN; Jones, K; Tan, M; Khan, A; Harris, V; McDonald, F; Lalondrelle, S; Mohammed, K; Thomas, K; Thompson, A; Kumar, P; Dearnaley, D; Horwich, A; Huddart, R (2016-04)
      PURPOSE:Image guided adaptive radiation therapy offers individualized solutions to improve target coverage and reduce normal tissue irradiation, allowing the opportunity to increase the radiation tumor dose and spare normal ...
    • Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations. 

      Bancroft, EK; Saya, S; Page, EC; Myhill, K; Thomas, S; Pope, J; Chamberlain, A; Hart, R; Glover, W; Cook, J; Rosario, DJ; Helfand, BT; Hutten Selkirk, C; Davidson, R; Longmuir, M; Eccles, DM; Gadea, N; Brewer, C; Barwell, J; Salinas, M; Greenhalgh, L; Tischkowitz, M; Henderson, A; Evans, DG; Buys, SS; IMPACT Study Steering Committee; IMPACT Collaborators; Eeles, RA; Aaronson, NK (2019-02)
      OBJECTIVES:To report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi-national investigation of targeted prostate cancer (PCa) screening among men with a known pathogenic ...
    • Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. 

      Wedge, DC; Gundem, G; Mitchell, T; Woodcock, DJ; Martincorena, I; Ghori, M; Zamora, J; Butler, A; Whitaker, H; Kote-Jarai, Z; Alexandrov, LB; Van Loo, P; Massie, CE; Dentro, S; Warren, AY; Verrill, C; Berney, DM; Dennis, N; Merson, S; Hawkins, S; Howat, W; Lu, Y-J; Lambert, A; Kay, J; Kremeyer, B; Karaszi, K; Luxton, H; Camacho, N; Marsden, L; Edwards, S; Matthews, L; Bo, V; Leongamornlert, D; McLaren, S; Ng, A; Yu, Y; Zhang, H; Dadaev, T; Thomas, S; Easton, DF; Ahmed, M; Bancroft, E; Fisher, C; Livni, N; Nicol, D; Tavaré, S; Gill, P; Greenman, C; Khoo, V; Van As, N; Kumar, P; Ogden, C; Cahill, D; Thompson, A; Mayer, E; Rowe, E; Dudderidge, T; Gnanapragasam, V; Shah, NC; Raine, K; Jones, D; Menzies, A; Stebbings, L; Teague, J; Hazell, S; Corbishley, C; CAMCAP Study Group; de Bono, J; Attard, G; Isaacs, W; Visakorpi, T; Fraser, M; Boutros, PC; Bristow, RG; Workman, P; Sander, C; TCGA Consortium; Hamdy, FC; Futreal, A; McDermott, U; Al-Lazikani, B; Lynch, AG; Bova, GS; Foster, CS; Brewer, DS; Neal, DE; Cooper, CS; Eeles, RA (2018-05)
      Prostate cancer represents a substantial clinical challenge because it is difficult to predict outcome and advanced disease is often fatal. We sequenced the whole genomes of 112 primary and metastatic prostate cancer ...